ZOL
ZOLEDRONIC ACID
Created: | 2005-06-06 |
Last modified: | 2021-03-01 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 26 |
Chiral Atom Count | 0 |
Bond Count | 26 |
Aromatic Bond Count | 5 |
Chemical Component Summary | |
---|---|
Name | ZOLEDRONIC ACID |
Synonyms | (1-HYDROXY-2-IMIDAZOL-1-YLETHYLIDENE)DIPHOSPHONIC ACID |
Systematic Name (OpenEye OEToolkits) | (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl)phosphonic acid |
Formula | C5 H10 N2 O7 P2 |
Molecular Weight | 272.09 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 10.04 | O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O |
SMILES | CACTVS | 3.341 | OC(Cn1ccnc1)([P](O)(O)=O)[P](O)(O)=O |
SMILES | OpenEye OEToolkits | 1.5.0 | c1cn(cn1)CC(O)(P(=O)(O)O)P(=O)(O)O |
Canonical SMILES | CACTVS | 3.341 | OC(Cn1ccnc1)([P](O)(O)=O)[P](O)(O)=O |
Canonical SMILES | OpenEye OEToolkits | 1.5.0 | c1cn(cn1)CC(O)(P(=O)(O)O)P(=O)(O)O |
InChI | InChI | 1.03 | InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14) |
InChIKey | InChI | 1.03 | XRASPMIURGNCCH-UHFFFAOYSA-N |
Drug Info: DrugBank
DrugBank ID | DB00399 |
---|---|
Name | Zoledronic acid |
Groups | approved |
Description | Zoledronic acid, or CGP 42'446,[A203120] is a third generation, nitrogen containing bisphosphonate similar to [ibandronic acid], [minodronic acid], and [risedronic acid].[A203111] Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone.[L13712,L13715,L13721] Zoledronic acid was first described in the literature in 1994.[A203120] Zoledronic acid was granted FDA approval on 20 August 2001.[L13712] |
Synonyms |
|
Brand Names |
|
Indication | Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women.[L13712,L13715,L13721] Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.[L13712,L13715,L13721] |
Categories |
|
ATC-Code |
|
CAS number | 118072-93-8 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Geranylgeranyl pyrophosphate synthase | MEKTQETVQRILLEPYKYLLQLPGKQVRTKLSQAFNHWLKVPEDKLQIII... | unknown | inhibitor |
Hydroxylapatite | - | unknown | antagonist,binder |
Farnesyl pyrophosphate synthase | MPLSRWLRSVGVFLLPAPYWAPRERWLGSLRRPSLVHGYPVLAWHSARCW... | unknown | inhibitor |
Multidrug resistance-associated protein 1 | MALRGFCSADGSDPLWDWNVTWNTSNPDFTKCFQNTVLVWVPCFYLWACF... | unknown | substrate |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL924 |
PubChem | 68740 |
ChEMBL | CHEMBL924 |
ChEBI | CHEBI:46557 |